Quince Therapeutics, Inc.
QNCX
$34.04
$1.635.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 45.58% | -47.78% | -6.97% | 7.71% | -100.49% |
| Total Depreciation and Amortization | -17.98% | -23.66% | -74.89% | -56.44% | -48.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -159.87% | 17.23% | -34.27% | -58.55% | 242.94% |
| Change in Net Operating Assets | 254.64% | 2,753.51% | 206.53% | 193.48% | 647.81% |
| Cash from Operations | -19.00% | -29.84% | -26.51% | -28.01% | -43.66% |
| Capital Expenditure | 44.26% | -36.96% | -225.00% | -344.12% | -480.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.13% | 6.38% | 41.77% | 132.97% | 11,933.17% |
| Cash from Investing | 1.83% | 6.02% | 58.38% | 169.34% | 1,102.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 26,793.44% | 7,859.56% | 5,529.43% | 4,865.41% | -56.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | 658.94% | 475.06% | 436.48% | 3,153.08% | -1,823.67% |
| Foreign Exchange rate Adjustments | -1,923.96% | -149.35% | 256.25% | 1,524.00% | -65.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 174.01% | 97.23% | 119.92% | 160.54% | 43.61% |